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ABSTRACT
Objectives To review evidence supporting use of
fluoroquinolones as first line agents over other antibiotics
for treating typhoid and paratyphoid fever (enteric fever).
DesignMeta-analysis of randomised controlled trials.
Data sources Cochrane Infectious Diseases Group
specialised register, CENTRAL (issue 4, 2007), Medline
(1966-2007), Embase (1974-2007), LILACS (1982-2007),
selected conferences, reference lists, and ongoing trial
register (November 2007).
Review methods Trials comparing fluoroquinolones with
chloramphenicol, cephalosporins, or azithromycin in
culture-proven enteric fever were included. Two reviewers
extracted data and assessed methodological quality.
Odds ratios with 95% confidence intervals were
estimated. Trials recruiting over 60% children were
analysed separately from trials on adults. Primary
outcomes studied were clinical failure, microbiological
failure, and relapse.
Results Twenty trials were included. Trials were small and
often of limited methodological quality. Only 10 trials
concealed allocation and only threewere blinded. In trials
on adults, fluoroquinolones were not significantly
different from chloramphenicol for clinical failure (594
participants) or microbiological failure (n=378), but
reduced clinical relapse (odds ratio 0.14 (95%confidence
interval 0.04 to 0.50), n=467, 6 trials). Azithromycin and
fluoroquinolones were comparable (n=152, 2 trials).
Compared with ceftriaxone, fluoroquinolones reduced
clinical failure (0.08 (0.01 to 0.45), n=120, 3 trials) but
not microbiological failure or relapse. Compared with
cefixime, fluoroquinolones reduced clinical failure (0.05
(0.01 to 0.24), n=238, 2 trials) and relapse (0.18 (0.03 to
0.91), n=218, 2 trials). In trials on children infected with
nalidixic acid resistant strains, older fluoroquinolones
(ofloxacin) produced more clinical failures than
azithromycin (2.67 (1.16 to 6.11), n=125, 1 trial), but
there were no differences with newer fluoroquinolones
(gatifloxacin, n=285, 1 trial). Fluoroquinolones and
cefixime were not significantly different (n=82, 1 trial).
Conclusions In adults, fluoroquinolones may be better
than chloramphenicol for preventing clinical relapse.
Data were limited for other comparisons, particularly for
children.
INTRODUCTION
Enteric fever (typhoid or paratyphoid fever) caused by
Salmonella serotype Typhi (S Typhi) or Salmonella ser-
otype Paratyphi (S Paratyphi) remains endemic in
many areas of the developing world, causing over 26
million infections and over 200 000 deaths annually.1
The incidence is highest in south-central Asia and
South East Asia (over 100/100 000 cases/year),1 with
the highest burden of disease in children aged
2-15 years.2-9S Typhi represents the commonest cause
of bacteraemia in this age group,4 6 and annual typhoid
rates (confirmed by blood culture) in recent studies
from India, Pakistan, and Indonesia range from 149
to as high as 573 cases per 100 000 children.9 Other
regions contributing to global morbidity andmortality
include Africa, Latin America, the Caribbean, and
other parts of Asia.1
Fluoroquinolones are recommended as first line
therapy for children and adults infected with sensitive
as well as multidrug resistant (resistant to all three first
line inexpensive antibiotics, chloramphenicol, amoxi-
cillin, and co-trimoxazole) S Typhi and Paratyphi.10 A
summary11 of randomised controlled trials of enteric
fever concluded that fluoroquinolones had lower clin-
ical failures and shorter fever clearance times com-
pared with first line antibiotics and ceftriaxone and
cefixime. However, few trials enrolled children,12 and
a meta-analysis was not conducted.
The recommendation to use fluoroquinolones as
first line therapy for enteric fever, particularly in chil-
dren, irrespective of sensitivity patterns—and without
a thorough analysis and assessment of quality of evi-
dence—has had profound public health implications
for developing countries. These range from increasing
costs of treatment to alarming rates of drug resistance.
Strains of STyphi and Paratyphi with reduced suscept-
ibility to fluoroquinolones have rapidly emerged—
most displaying resistance to nalidixic acid and asso-
ciated with poor response to treatment. 9 13-34 Even
more alarming are reports of high level fluoroquino-
lone resistance.25 29 30 32 34-38 Although newer generation
fluoroquinolones such as gatifloxacin are active against
nalidixic acid resistant strains,39 40 it may only be a
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matter of time before resistance to newer agents
becomes widespread if indiscriminate and inappropri-
ate use of fluoroquinolones for any febrile illness con-
tinues in endemic areas.41
However, although antimicrobial resistance patterns
show wide regional variations,9 some reports suggest
thatmultidrug resistant strains of STyphi have declined
from previously high figures,1924252932 3442-45 indicating
Characteristics and methodological quality of trials included in meta-analysis
Study
Country
and year of study
(if stated)
Participants’ age group,
setting, culture site, and
severity at enrollment*
No of participants
(in fluoroquinolone
group: other group)
Methodological
quality of trials†
Drug regimens
used‡
Fluoroquinolone versus chloramphenicol
Quintero 198863
(conference abstract)
Mexico Adult dosages, inpatients,
blood culture, severity
unknown§
26 (13:13) Randomisation unclear, allocation
concealment unclear, double
blinded, follow-up adequate
Ciprofloxacin 750 mg orally 3 times a
day. Chloramphenicol 750 mg orally 4
times a day. Duration not mentioned
Bran 199164 (conference
abstract)
Guatemala Adult dosages, inpatients,
blood and/or bone marrow
culture, severity unknown§
102 (51: 51)§ Randomisation unclear, allocation
concealment unclear, double
blinded, follow-up adequate
Ciprofloxacin500mgorally twiceaday
for 10 days. Chloramphenicol 750 mg
orally every 6 hours for 14 days
Gottuzzo 199265 — Adult inpatients, mainly blood
culture, severity unknown§
98 (49:49) Randomisation unclear, allocation
concealment unclear, double
blinded, follow-up adequate
Ciprofloxacin 500 mg orally every 12
hours for 10 days. Chloramphenicol
750mgorallyevery6hours for14days
Morelli 199266 Italy 1985-90 Adult inpatients, blood
culture, severity unknown
156([30:36:20:20]:30)¶ Randomisation adequate,
allocation concealment unclear,
unblinded, follow-up adequate
Ofloxacin 300mg, pefloxacin 400mg,
ciprofloxacin 500 mg, enoxacin
300 mg (all orally every 8 hours for
15 days) Chloramphenicol 500 mg
orally every 6 hours for 15 days
Yousaf 199267 Pakistan 1989-92 Adult inpatients, blood
culture, severity unknown§
50 (25:25) Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up inadequate
Ofloxacin 200mgorally twice a day for
14 days. Chloramphenicol 50 mg/kg/
day orally, 30 mg/kg/day when
afebrile, for 14 days
Abejar 199368 Philippines Adult inpatients, blood
culture, severity unknown
30 (15:15) Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up adequate
Fleroxacin 400mgorallyonceaday for
10 days. Chloramphenicol 50 mg/kg/
day orally in 3 divided doses every 8
hours for 14 days
Arnold 199369 Multicentre: South
America,
Indonesia, etc§
Adult inpatients, blood
culture, no major
complications
91 ([24:33]:34) Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up adequate
Fleroxacin 400mgorallyonceaday for
7days. Fleroxacin400mgorallyoncea
day for 14 days. Chloramphenicol
50 mg/kg/day orally for 14 days
Cristiano 199570 Italy 1991-3 Adult inpatients, blood
culture, all severe cases
60 (30:30) Randomisation adequate,
allocation concealment unclear,
unblinded, follow-up adequate
Pefloxacin 1200 mg IV in 3 divided
doses every 8 hours for 5 days then
orally for10days.Chloramphenicol2g
orally in 4 divided doses every 6 hours
for 15 days
Gasem 200371 Indonesia 1997 Adult inpatients, blood and/or
bone marrow culture, no
severe complications
55 (28:27) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up adequate
Ciprofloxacin500mgorally twiceaday
for 7 days. Chloramphenicol 500 mg
orally four times a day for 14 days
Phongmany 200572** Laos 2001-3 Adult inpatients, blood
culture, uncomplicated
50 (27:23) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up adequate
Ofloxacin 15 mg/kg/day orally in 2
divided doses for 3 days.
Chloramphenicol 50mg/kg/day orally
in 4 divided doses for 14 days
Fluoroquinolone versus ceftriaxone
Wallace 199373 Bahrain Adult inpatients, blood
culture, severity unknown
42 (20:22) Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up adequate
Ciprofloxacin500mgorally twiceaday
for 7 days. Ceftriaxone 3 g/day IV for
7 days
Smith 199474** Vietnam 1992-3 Adult inpatients, blood and/or
bone marrow (n=44) stool
(n=3) culture, uncomplicated
47 (22:25) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate
Ofloxacin200mgorallyevery12hours
for 5 days. Ceftriaxone 3 g/day IV for
3 days
Tran 199475** Vietnam 1992-3 Adult inpatients, blood
culture, uncomplicated
31 (16:15) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate
Fleroxacin 400mgorallyonceaday for
7days. Ceftriaxone2g IVoncedaily for
5 days
Fluoroquinolone versus cefixime
Yu, 199876 (in Chinese) China Adult inpatients, blood or
bone marrow culture, severe
cases included§
80 (40:40) Randomisation unclear, allocation
concealment unclear, unblinded,
follow-up adequate
Levofloxacin 200mgorally twice a day
for 10 days. Cefixime 200 mg orally
twice a day for 10 days
Cao 199977** Vietnam 1995-6 Child (<15 years old)
inpatients, blood culture,
uncomplicated
82 (38:44) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate
Ofloxacin 10 mg/kg/day orally in 2
divided doses for 5 days. Cefixime
20 mg/kg/day orally in 2 divided
doses for 7 days
Pandit 200739** Nepal 2005 Adult and child (35.5% < 14
years) outpatients, blood
culture, uncomplicated
158 (88:70) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate
Gatifloxacin10mg/kg/day orally once
a day for 7 days. Cefixime 20 mg/kg/
day orally in2 divideddoses for 7 days
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that chloramphenicol could still be used in some ende-
mic areas.On the other handmultidrug resistant strains
of S Paratyphi may be emerging,24294647 which under-
scores the complexities of treatment and limited alter-
natives available.48
This meta-analysis was undertaken to determine the
strength of evidence supporting use of fluoroquino-
lones over chloramphenicol, ceftriaxone, cefixime,
and azithromycin for treating enteric fever in children
and adults.49
METHODS
Search strategy and selection criteria
We searched the Cochrane Infectious Diseases
Group’s specialised register (November 2007),
Cochrane central register of controlled trials (CEN-
TRAL, issue 4, 2007), Medline (1966 to November
2007), Embase (1974 to November 2007), and
LILACS (1982 to November 2007) using text words
and medical subject headings (MeSH) “typhoid
fever,” “enteric fever,” “paratyphoid fever,” “Salmo-
nella Typhi,” “Salmonella Paratyphi” combined with
the Cochrane Collaboration’s search strategy.50 A
complete list of search terms used is available.49 We
identified relevant trials in all languages, searched
selected conference proceedings, authors’ files, refer-
ence lists, and the meta-Register of Controlled Trials
(mRCT), and contacted experts for relevant ongoing
or unpublished trials.49
One reviewer screened titles and abstracts, and
potentially relevant trials were further evaluated inde-
pendently by two reviewers using pre-designed elig-
ibility forms. Trials were included if they were
randomised and compared fluoroquinolone with
another antibiotic in enteric fever confirmed with
blood or bone marrow culture.
Data abstraction and methodological assessment
Two reviewers independently extracted data using
piloted data extraction forms, compared data, and
resolved disagreements. Primary outcomes (measured
at time points described by investigators) were clinical
failure (presence of symptoms or development of com-
plications necessitating change in or prolongation of
antibiotic therapy), microbiological failure (positive
culture from blood, bonemarrow, or any sterile anato-
mical site), and relapse (recurrence of symptomswith a
positive culture from blood, bonemarrow, or any ster-
ile anatomical site). Secondary outcomes included
fever clearance time (time taken in hours from the
start of therapy to defervescence, as defined by
authors), convalescent faecal carriage (positive faecal
culture detected at any time after end of treatment up
to one year of follow-up), cost of therapy, length of
hospitalisation, complications, and adverse events.49
We contacted study authors for additional data or to
clarify data.
Two reviewers independently assessed methodolo-
gical quality of trials based on the method of randomi-
sation (generation of allocation sequence), allocation
concealment, blinding, and follow-up of participants
with culture-proven enteric fever (see table). 49 51 We
conducted an available case analysis and derived the
proportion of participants lost to follow-up at final
outcome.
Study
Country
and year of study
(if stated)
Participants’ age group,
setting, culture site, and
severity at enrollment*
No of participants
(in fluoroquinolone
group: other group)
Methodological
quality of trials†
Drug regimens
used‡
Fluoroquinolone versus azithromycin
Girgis 199978** Egypt 1997-8 Adult inpatients, blood (n=62)
stool (n=2) culture,
uncomplicated
64 (28:36) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up adequate
Ciprofloxacin500mgorally twiceaday
for 7days.Azithromycin1gorallyonce
on day 1, then 500 mg once a day for
6 days (total of 7 days)
Chinh 200079** Vietnam Adult inpatients, blood
culture, uncomplicated
88 (44:44) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate
Ofloxacin 200 mg orally twice a day
(8 mg/kg/day) for 5 days.
Azithromycin 1 g orally daily
(20 mg/kg/day) for 5 days
Parry 200780** Vietnam
1998-2002
Adult and child (87% <15
years) inpatients, blood and/
or bone marrow culture,
uncomplicated††
125 (63:62) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up inadequate
Ofloxacin 20 mg/kg/day orally in 2
divideddoses for 7days. Azithromycin
10 mg/kg/day orally once a day for
7 days
Dolecek 200840** Vietnam
(3 hospitals)
2004-5
Adult and child (73% <15
years) inpatients, blood and/
or bone marrow culture,
uncomplicated
285 (145:140) Randomisation adequate,
allocation concealment adequate,
unblinded, follow-up adequate
Gatifloxacin10mg/kg/day orally once
a day for 7 days. Azithromycin 20mg/
kg/day orally once a day for 7 days
*Severity of fever at enrollment was as defined by trial investigators.
†Quality assessment as follows. Randomisation: adequate (methods such as computer generated random numbers or use of a random number table), inadequate (methods such as
assignment based on day of presentation or alternation), unclear (method not described). Allocation concealment: adequate (methods such as use of sealed envelopes), inadequate (such
as unsealed envelopes), unclear (no information provided). Blinding: single (either care provider/outcome assessor or participants were unaware of treatment), double (participants and care
provider/outcome assessor were unaware of treatment), open (all parties were aware of treatment). Follow-up: adequate (≥90% of participants with culture confirmed infection followed up),
inadequate (<90% of such participants followed up).
‡For trials that compared different fluoroquinolones (such as ofloxacin and ciprofloxacin) or different durations of fluoroquinolones (such as 7 and 14 days), we combined all
fluoroquinolone groups for comparison with groups receiving the non-fluoroquinolone antibiotic.
§Some information not explicitly stated, but assumed based on information in trial.
¶The norfloxacin group was not included in this meta-analysis (see text for explanation).
**Author provided additional information.
††A third arm in this study, involving combination of treatments, was not included in this meta-analysis
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Statistical analysis and stratifications
We conducted meta-analyses using Review Manager
5,52 with odds ratios for dichotomous data and mean
differences for continuous data, presented with 95%
confidence intervals. We used Mantel-Haenszel odds
ratios since there were limited data and few trials.53
Because the events are relatively rare, the estimated
odds ratios can be considered similar to risk ratios.53
We did not combine trials recruiting children (trials
with >60% participants who were <16 years) with trials
recruiting adults (≥16 years or “adults” as described by
the investigators), since enteric fever differs in severity,
clinical manifestations, and outcome in children and
adults,54-57 and because of generic differences in drug
pharmacokinetics and pharmacodynamics in children
and adults. Adverse events from fluoroquinolones are
still not clearly delineated in children.5859 We stratified
results bypresence ofmultidrug resistant strains (for trials
involving chloramphenicol) and nalidixic acid resistant
strains (all trials). (All stratifications are presented
elsewhere.49) We generated a funnel plot to assess publi-
cationbias for comparisonswithmore than five trials.We
assessedheterogeneity by visual inspectionof graphs and
χ2 test for homogeneity (at 10% level of significance) and
explained heterogeneity by exploring differences in drug
doses or durations, severity of enteric fever (as defined by
investigators), and time points of outcomemeasurement.
We used a fixed effects model to pool data. When we
found significant heterogeneity we used a random effects
model if it was still considered appropriate to pool data.
RESULTS
Seventy potentially relevant trials were evaluated (fig 1
shows the numbers of studies evaluated at each stage).
Details of the excluded studies and the reasons for
exclusion are available. 49 We excluded trials using
norfloxacin60-62 since this is not recommended for
treating enteric fever because of its low oral
bioavailability. 10 We included 20 trials in the present
analysis—fluoroquinolones were compared with
chloramphenicol (10 trials), 63-72 ceftriaxone (three
trials), 73-75 cefixime (three trials), 39 76 77 and azithromy-
cin (four trials). 40 78-80
Study characteristics and methodological quality
The table details the trials’ characteristics. Only three
recruited children exclusively or predominantly.407780
Sample sizes were small (ranging from 2663 to 28540).
Duration of fluoroquinolone treatment ranged from
three days72 to 15 days.6670 Twelve trials had adequate
methods of randomisation,3940 6670-72747577-80 10 ofwhich
had adequate allocation concealment.39 40 71 72747577-80
Three were “double blinded.”63-65 Final follow-up of
confirmed cases was adequate in 13.4063-6668-737678 Defi-
nitions and time points of measurements for outcomes
such as clinical andmicrobiological failure showed con-
siderable variations.49
Comparisons involving adults
Fluoroquinolone versus chloramphenicol
Three of the 10 included trials did not clarify the pro-
portion of multidrug resistant strains.65 67 69 Multidrug
resistant strains were absent in all other trials, except
one.72 One trial had no isolates with nalidixic acid
resistance72—the others did not report this informa-
tion.
The meta-analysis showed no significant differences
between fluoroquinolones and chloramphenicol for
clinical failure (odds ratio 0.65 (95% confidence inter-
val 0.25 to 1.72), n=594, nine trials), but confidence
intervals were wide (fig 2). The results were of border-
line significance in favour of fluoroquinolones for
microbiological failure (0.43 (0.18 to 1.03), n=378, six
trials). The odds of clinical relapsewere reduced signif-
icantly, by 86%, with fluoroquinolones (0.14 (0.04 to
0.50), n=467, six trials). Fluoroquinolone use was asso-
ciated with a significantly lower mean fever clearance
time (mean difference −25.93 hours (95% confidence
interval −40.12 to −11.74), n=129, three trials) (see
extra fig A on bmj.com) as well as convalescent faecal
carriage (0.17 (0.04 to 0.70), n=298, three trials). There
was significant heterogeneity (P<0.00001) between the
two trials comparing length of hospitalisation, which
could have been due to differences in fluoroquinolone
treatment durations (3 days v 7 days). A random effects
model showed no differences (−3.13 days (−8.52 to
2.26), n=105, two trials).
Sensitivity analysis (not shown)—When we restricted
the analysis to trials of better methodological quality
(that is, adequate methods of randomisation and
allocation concealment) there was no change in
results for clinical failure (n=105)71 72 or microbiologi-
cal failure (n=45).71 For relapse, when we excluded
trials which did not clearly define or did not confirm
relapse using cultures, we retained only one trial
Studies not eligible (n=104)
Did not include fluoroquinolones (n=91)
Did not include participants with 
typhoid or paratyphoid fever (n=9)
Not randomised controlled trials (n=4)
Trials not included (n=32)†
Not or quasi-randomised (n=15)
Miscellaneous reasons (n=10)‡
Duplicate publications (n=3)
Full text not retrievable (n=2)
Ongoing trials (n=2)
Trials not presented (n=18)†§
Comparing:
Different fluoroquinolone durations (n=8)
Different fluoroquinolones (n=4)
Norfloxacin (n=3)
Co-trimoxazole (n=2)
Ampicillin/amoxicillin (n=1)Trials presented in this report (n=20)
Fluoroquinolones versus:
 Chloramphenicol (n=10)
 Azithromycin (n=4)
 Ceftriaxone (n=3)
 Cefixime (n=3)
Trials included (n=38)†
Studies considered
for detailed evaluation
(n=70)
Studies identified (n=174)
Cochrane databases, Medline, 
Embase,LILACS, supplementary 
search* (November 2007)
Fig 1 | Studies evaluated at each stage of the meta-analysis. (*Supplementary search includes:
reference lists, authors’ files, contacting experts, selected conference proceedings, on-going
trial register. †See Cochrane review49 for further details or analyses. ‡Includes sample size <5,
comparing different formulations/routes of same fluoroqinolone, not enough information
presented in published report. §Trials contributing to more than 1 category counted only once.)
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(n=91)69 with blood culture confirmed relapses and
did not find any difference between fluoroquinolones
and chloramphenicol, although confidence intervals
were wide. The only methodologically adequate trial
(n=55)71 did not report any clinical relapses during
hospitalisation, without longer follow-up. Fever
clearance times were significantly lower with fluoro-
quinolone use (−27.56 hours (−43.38 to −11.75),
n=103).71 72 Both trials reporting length of hospital
stay were of adequate methodological quality; there
were no data for convalescent faecal carriage from
these trials.
Funnel plots—Thenumber of trials (4 to 7) in included
funnel plots for outcomes clinical failure, microbiolo-
gical failure, and relapse was well below the recom-
mended number of trials (10) for meaningful
interpretation. No asymmetry was detected for clinical
failure, but some asymmetry was detected for micro-
biological failure and relapse.49 (See extra fig B on
bmj.com.)
Fluoroquinolone versus cefixime
One open trial conducted on mainly adult outpatients
presenting to hospital had adequate methods of
Clinical failure
No of events
Study Fluoroquinolone Chloramphenicol Weight (%) Odds ratio (95% CI) Odds ratio (95% CI)
Quintero-Perez198863 0/13 1/13 14.5 0.31 (0.01 to 8.30)
Gottuzzo 199265 1/48 0/48 4.8 3.06 (0.12 to 77.09)
Morelli 199266 4/106 0/30 7.4 2.68 (0.14 to 51.15)
Yousaf 199267 1/25 2/25 19.2 0.48 (0.04 to 5.65)
Abejar 199368 0/15 0/15 — Not calculable
Arnold 199369 0/57 1/34 18.6 0.19 (0.01 to 4.90)
Cristiano 199570 0/30 0/30 — Not calculable
Gasem 200371 1/28 2/27 19.6 0.46 (0.04 to 5.43)
Phongmany 200572 0/27 1/23 15.9 0.27 (0.01 to 7.02)
Total 7/349 7/245 100 0.65 (0.25 to 1.72)
Microbiological failure
Heterogeneity: χ2=2.92, df=6, P=0.82, I2=0%
Test for overall effect Z=0.86, P=0.39
Bran 199164 0/51 0/51 — Not calculable
Yousaf 199267 1/25 3/25 17.9 0.31 (0.03 to 3.16)
Abejar 199368 0/15 1/15 9.0 0.31 (0.01 to 8.28)
Arnold 199369 2/57 5/34 37.6 0.21 (0.04 to 1.15)
Cristiano 199570 0/30 0/30 — Not calculable
Gasem 200371 7/23 8/22 35.4 0.77 (0.22 to 2.65)
Total 10/201 17/177 100 0.43 (0.18 to 1.03)
Heterogeneity: χ2=1.62, df=3, P=0.65, I2=0%
Test for overall effect Z=1.90, P=0.06
Relapse
Gottuzzo 199265 0/47 4/48 27.2 0.10 (0.01 to 1.99)
Morelli 199266 0/106 3/30 33.4 0.04 (0.00 to 0.74)
Abejar 199368 0/15 1/15 9.0 0.31 (0.01 to 8.28)
Arnold 199369 1/57 2/34 15.2 0.29 (0.02 to 3.28)
Cristiano 199570 0/30 2/30 15.2 0.19 (0.01 to 4.06)
Gasem 200371 0/28 0/27 — Not calculable
Total 1/283 12/184 100 0.14 (0.04 to 0.50)
Heterogeneity: χ2=1.39, df=4,=0.85, I2=0%
Test for overall effect Z=3.04, P=0.002
0.10.001 1 10 1000
0.10.001 1 10 1000
0.10.001 1 10 1000
Favours fluoroquinolone Favours chloramphenicol
Fig 2 | Forest plots for trials of fluoroquinolones versus chloramphenicol for treating enteric fever in adult inpatients. Details of studies reporting proportion of
multidrug resistant and nalidixic acid resistant strains are in text. See Cochrane review49 for stratifications.
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randomisation and allocation concealment but inade-
quate follow-up.39 Community medical auxiliaries con-
ducted home based assessments twice daily and
provided directly observed treatment with study drugs;
all participants were also seen at the hospital on day 10.39
Althoughnalidixic acid resistancewaspresent, the newer
generation fluoroquinolone used (gatifloxacin) is unaf-
fected by nalidixic acid resistance.39 The other trial on
adult inpatients hadunclearmethodology, and resistance
data were not extractable.76 The meta-analysis showed a
significant reduction in clinical failure (odds ratio 0.05
(95% confidence interval 0.01 to 0.24), n=238) as well
as relapse in the fluoroquinolone group (0.18 (0.03 to
0.91), n=218) (fig 3). No differences were detected for
microbiological failure (0.14 (0.02 to 1.23), n=238), but
the confidence interval was wide. There was a significant
reduction in fever clearance time with fluoroquinolones
(mean difference −41.69 hours (−54.96 to −28.42),
n=238) (see extra fig A). There were no differences in
convalescent faecal carriers (0.26 (0.01 to 6.50), n=227).
Fluoroquinolones versus ceftriaxone
All three trials recruiting adult inpatients were
open.73-75 Two had adequate methods of randomisa-
tion and allocation concealment but inadequate fol-
low-up.74 75 Nalidixic acid resistant strains were
absent in one74 and were not reported in the others.
The meta-analysis showed a significantly lower odds
of clinical failure with fluoroquinolones (0.08 (0.01 to
0.45), n=120), but there was no difference in microbio-
logical failure (0.32 (0.03 to 3.17), n=119) or relapse
(0.34 (0.03 to 3.47), n=81), although confidence inter-
vals were wide (fig 4). Fever clearance time was signifi-
cantly lower with fluoroquinolones (−101.20 hours
(−129.21 to −73.19), n=76) (see extra fig A). There
were no differences in convalescent faecal carriage
(0.35 (0.01 to 9.08) n=81).
Fluoroquinolones versus azithromycin
Both open trials recruiting adult inpatients, had ade-
quate methods of randomisation and allocation
concealment.78 79 One had adequate follow-up.78
There was a high proportion of nalidixic acid resistant
strains in one (52%),79 but this information was not
reported in the other trial. There were no significant
differences in clinical failure (3.32 (0.63 to 17.43),
n=152), microbiological failure (2.05 (0.18 to 23.44),
n=152), or relapse (6.94 (0.31 to 154.85), n=102),
although the confidence intervals were wide and com-
parisons lacking in statistical power (see extra fig C on
bmj.com). There were no significant differences in
fever clearance times (−8.95 hours (−20.09 to 2.19),
n=152) (extra fig A) or length of hospital stay
(−0.90 days (−0.32 to 2.12), n=152). There was a signif-
icant increase in convalescent faecal carriage with
fluoroquinolone use (21.33 (1.18 to 386), n=133; this
was measured early on days 2-3 after end of
treatment).79
Comparisons involving children
Fluoroquinolone versus cefixime
We found only one open trial recruiting hospitalised
children, with adequate methods of randomisation
and allocation concealment but inadequate follow-
up.77 No child was infected by a nalidixic acid resistant
strain. Reduction in clinical failure was of borderline
significance in favour of fluoroquinolones (0.12 (0.01
to 1.02), n=82). Therewere no significant differences in
microbiological failure (0.22 (0.01 to 4.74), n=82) or
relapse (0.32 (0.01 to 8.26), n=40). Although a trend
favouring fluoroquinolone can be seen, the confidence
intervals were wide. There was a significant reduction
in fever clearance time (−91.00 hours (−115.89 to
−66.11), n=78) and length of hospital stay with fluoro-
quinolones (−3 days (−4.53 to −1.47 days), n=81). No
convalescent faecal carriers were reported.
Study Fluoroquinolone Cefixime Weight (%) Odds ratio (95% CI) Odds ratio (95% CI)
Yu 199876 0/40 3/40 14.2 0.13 (0.01 to 2.65)
Pandit 200739 1/88 19/70 85.8 0.03 (0.00 to 0.24)
Total 1/128 22/110 100 0.05 (0.01 to 0.24)
Heterogeneity: χ2=0.63, df=1, P=0.43, I2=0%
Test for overall effect Z=3.66, P<0.001
Microbiological failure
Yu 199876 0/40 4/40 72.8 0.10 (0.01 to 1.92)
Pandit 200739 0/88 1/70 27.2 0.26 (0.01 to 6.53)
Total 0/128 5/110 100 0.14 (0.02 to 1.23)
Heterogeneity: χ2=0.19, df=1, P=0.66, I2=0%
Test for overall effect Z=1.77, P=0.08
0.10.001 1 10 1000
0.10.001 1 10 1000
Clinical failure
No of events
Favours fluoroquinolone Favours cefixime
Fig 3 | Forest plots for trials of fluoroquinolones versus cefixime for treating enteric fever in adult outpatients and inpatients. There were no relapses in either
arm in Yu et al 1998.76 Pandit et al 200739 reported 2/87 v 6/51 relapses (odds ratio 0.18 (95% confidence interval 0.03 to 0.91). Details of studies reporting
proportion of nalidixic acid resistant strains are in text.
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Fluoroquinolones versus azithromycin
Both open trials on mostly paediatric inpatients, with
adequate methods of randomisation and allocation
concealment, had uniformly high proportions of nali-
dixic acid resistant strains (98%80 and 96%40 in fluoro-
quinolone arms). One trial used gatifloxacin,40 which
is active against nalidixic acid resistant strains; we
therefore did not combine these trials in ameta-analy-
sis. With ofloxacin there was a significant increase in
clinical failure (2.67 (1.16 to 6.11), n=125), no signifi-
cant differences in microbiological failure (0.98 (0.13
to 7.21), n=125), and no relapses at one month follow-
up (<90% participants followed).80 Ofloxacin use sig-
nificantly increased fever clearance time (57.60 hours
(28.31 to 86.89), n=125) and convalescent faecal car-
riage (14.64 (1.84 to 116.48), n=124) and a borderline
increase in length of hospitalisation (1.10 days (0.00 to
2.20), n=125). In the trial of gatifloxacin versus azi-
thromycin (n=285) there were no significant differ-
ences in clinical or microbiological failure (0.96 (0.30
to 3.06) and 0.64 (0.11 to 3.88)), relapse (6.64 (0.34 to
129.74), n=264), fever clearance time (0.73 hours
(−12.97 to 14.43)), length of hospital stay (0.19 days
(−0.49 to 0.87)), or convalescent faecal carriage (2.89
(0.12 to 71.58), n=268), although confidence intervals
were wide.40
Other outcomes
Complications—There were significantly lower compli-
cations with gatifloxacin compared with azithromycin
(0.05 (0.00 to 0.94), n=285).40 No differences were
found in other trials of fluoroquinolones with
chloramphenicol,71 72 ceftriaxone,73-75 cefixime,39 77 or
azithromycin.78-80
Adverse events—There were no differences in non-ser-
ious adverse events with azithromycin,40 chloramphe-
nicol,67 68 70-72 or ceftriaxone.74 The meta-analysis of
trials comparing fluoroquinolone and cefixime
showed significant heterogeneity, and was combined
using a random effects model (3.30 (0.11 to 97.30),
n=238). There were no differences in serious adverse
events with ceftriaxone.74 75 Other trials either
reported no complications or adverse events in either
arm, or reported events without actual numbers of par-
ticipants experiencing these events. 49
DISCUSSION
Main findings and limitations
Even though enteric fevermost commonly affects chil-
dren in areas where it is endemic, this review shows the
paucity of evidence supporting the use of fluoroquino-
lones in this age group from adequately designed ran-
domised controlled trials. Adult inpatients are the
group most studied, although they form only a small
Study Fluoroquinolone Ceftriaxone Weight (%) Odds ratio (95% CI) Odds ratio (95%CI)
Wallace 199373 0/20 6/22 41.7 0.06 (0.00 to 1.18)
Smith 199474 0/22 6/25 41.1 0.07 (0.00 to 1.26)
Tran 199475 0/16 2/15 17.2 0.16 (0.01 to 3.71)
Total 0/58 14/62 100 0.08 (0.01 to 0.45)
Heterogeneity: χ2=0.24, df=2, P=0.89, I2=0%
Test for overall effect Z=2.87, P=0.004
Microbiological failure
Wallace 199373 0/20 0/22 — Not calculable
Smith 199474 0/22 1/25 47.1 0.36 (0.01 to 9.37)
Tran 199475 0/16 1/14 52.9 0.27 (0.01 to 7.25)
Total 0/58 2/61 100 0.32 (0.03 to 3.17)
Heterogeneity: χ2=0.01, df=1, P=0.90, I2=0%
Test for overall effect Z=0.98, P=0.33
Relapse
Wallace 199373 0/20 1/22 50.3 0.35 (0.01 to 9.08)
Smith 199474 0/11 1/12 49.7 0.33 (0.01 to 9.07)
Tran 199475 0/8 0/8 — Not calculable
Total 0/39 2/42 100 0.34 (0.03 to 3.47)
Heterogeneity: χ2=0.00, df=1, P=0.98, I2=0%
Test for overall effect Z=0.91, P=0.36
0.10.001 1 10 1000
0.10.001 1 10 1000
0.10.001 1 10 1000
Favours fluoroquinolone Favours ceftriaxone
Clinical failure
No of events
Fig 4 | Forest plots for trials of fluoroquinolones versus ceftriaxone for treating enteric fever in adult inpatients. Details of studies reporting proportion of
nalidixic acid resistant strains are in text. See Cochrane review49 for stratifications.
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proportion of overall typhoid burden. Even in this sub-
group, most trials were small with limited statistical
power and serious methodological limitations.
We did not find any trial comparing fluoroquino-
lones with chloramphenicol in children, and so cannot
make recommendations specific to this age group. In
trials comparing fluoroquinolones and chlorampheni-
col in adults data were insufficient to detect significant
differences in clinical or microbiological failure. Any
true treatment difference, if one existed, was obscured
by wide confidence intervals, and the role of chance
cannot be excluded as an explanation for these find-
ings. Microbiological failure, measured at varying
time points, was based on blood cultures, although
one reviewed trial71 also reportedbonemarrow culture
results for ciprofloxacin comparedwith chlorampheni-
col (67% v 100% positive cultures on day 5, P=0.04).
Although this difference was significant, it was smaller
than anticipated since penetration of ciprofloxacin
intracellularlywas expected to eradicate amuchhigher
proportion of STyphi.71Data suggest that fluoroquino-
lones were better than chloramphenicol for reducing
clinical relapse, but most investigators did not define
relapse explicitly and data are lacking for relapse con-
firmed by culture. The wide confidence intervals pro-
duced when we restricted our analyses to trials of
adequate methodological quality underscore the lim-
ited evidence available. As well as a lack of explicit
definitions for measured outcomes and variations in
times at which these were measured, resistance data
(multidrug resistant and nalidixic acid resistant) were
not explicitly reported, particularly in older trials.
While datawere limited for comparisons of fluoroqui-
nolones and cefixime in children, unblinded compari-
sons involving adults suggest that fluoroquinolones are
better than cefixime for reducing clinical failure and
relapse and better than ceftriaxone for reducing clinical
failure. The lack of methodological rigour—failure to
conceal allocation by some and failure to use blinding
in all—suggests that these results may have been influ-
enced by selection bias and observer bias andmay over-
estimate the benefit of fluoroquinolones compared with
older antibiotics.51 There were too few trials to ascertain
presence of publication bias using funnel plots. How-
ever, someasymmetryobserved formicrobiological fail-
ure and relapse for trials involving chloramphenicol
suggests the possibility of publication bias or failure to
publish smaller studies showingnon-significant results.81
Our results thus differ from those of a previous
review, a summary of randomised controlled trials of
enteric fever,11 which found fluoroquinolones to be
superior to chloramphenicol, ceftriaxone, and cefix-
ime for clinical failure and fever clearance times.
Although our data suggest that fluoroquinolones had
significantly lower fever clearance times compared
with chloramphenicol, cefixime, and ceftriaxone, the
analyses of fever clearance times must be interpreted
with caution.Mean fever clearance times often follow a
skewed distribution—although most patients clear
fever quickly, some take much longer times—so
meta-analyses conducted using arithmetic means may
not be accurate. The persistence of fever in some
patients despite apparent clearance of S Typhi and S
Paratyphi from the bloodstream has been attributed
to the continued production of pyrogenic
cytokines.82-85 This suggests that time taken to clear
fever may not be an adequate measure of antibiotic
efficacy, and consequently may not be an appropriate
end point in typhoid therapy trials. Some investigators
also did not specify whether clinical failures were
excluded or included in calculations of mean fever
clearance time.
Cost considerations
We could not compare the costs of fluoroquinolone
and other antibiotics because of lack of data from trials.
Although fluoroquinolones may be the least costly
alternative for multidrug resistant enteric fever, this
cost advantage has diminished with increasing num-
bers of strains resistant to older fluoroquinolones
such as ciprofloxacain and ofloxacin.913-38 Newer
fluoroquinolones such as gatifloxacin are effective
against nalidixic acid resistant strains,39 but more evi-
dence of efficacy compared with other antibiotics, tol-
erance, and safety is required,39 as well as close
monitoring of resistance patterns and check on indis-
criminate use. For children, one trial found that oflox-
acin performed poorly comparedwith azithromycin in
patients infected with nalidixic acid resistant strains,80
while data for azithromycin versus gatifloxacin are
limited.40
Applicability
Our results may be applicable only to hospitalised
adults with culture confirmed enteric fever—since
most of the trials enrolled such patients. Hospitalised
patients represent the more severe end of the spectrum
of enteric fever, and adults differ from children in dis-
ease presentation, severity, and complications.54-57 In
developing regions most patients with typhoid fever
are children—often managed as outpatients without
confirmation by culture.11 Indeed, rates of hospitalisa-
tion of primary care patients for culture confirmed
enteric fever have been under 1% with algorithm-
based early recognition and management (Z A Bhutta
et al, unpublished data). The widespread empiric use of
fluoroquinolones is also not generally recommended in
children because of the potential risk of arthropathy.5859
Future directions and policy implications
Appropriate treatment for enteric fever is a clinical and
public health challenge, with rising levels of drug resis-
tance and limited evidence for use of newer agents, par-
ticularly for children. Large, well designed, and
methodologically rigorous trials are needed to compare
fluoroquinolones with first line antibiotics in commu-
nity or outpatient settings, reflecting practice in low
income countries, with accurate reporting of resistance
data. Long term follow-up and monitoring of adverse
effects are also required. Investigators must standardise
definitions and time points of measurements of
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outcomes, particularly those of subjective nature, such
as clinical failure. The identification of strains with
reduced susceptibility to fluoroquinolones which do
not exhibit nalidixic acid resistance2027 indicates the
need for reporting and interpretation of fluoroquino-
lone minimum inhibitory concentrations. In addition
to objective studies of treatment efficacy and cost effec-
tiveness,weneedevaluationsof algorithmic approaches
to diagnosis and management of prolonged fever in
children in regions where typhoid is endemic.86 Such
protocols will guide antibiotic use and may curb rising
resistance. Surveillance systems for monitoring burden
of disease and resistance patterns are required.87
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